Serine and arginine rich splicing factor 1: a potential target for neuroprotection and other diseases
Ana M.Sandoval-Castellanos1
Anushka Bhargava2
Min Zhao3
Jun Xu4
Ke Ning5
1.Sheffield Institute of Translational Neuroscience,SITraN,The University of Sheffield,Sheffield,UK;Department of Ophthalmology&Vision Science,and Department of Dermatology,Institute for Regenerative Cures,University of California at Davis,School of Medicine,Sacramento,CA,USA2.Sheffield Institute of Translational Neuroscience,SITraN,The University of Sheffield,Sheffield,UK3.Department of Ophthalmology&Vision Science,and Department of Dermatology,Institute for Regenerative Cures,University of California at Davis,School of Medicine,Sacramento,CA,USA4.East Hospital,Tongji University School of Medicine,Shanghai,China5.Sheffield Institute of Translational Neuroscience,SITraN,The University of Sheffield,Sheffield,UK;East Hospital,Tongji University School of Medicine,Shanghai,China
摘要：Alternative splicing is the process of producing variably spliced mRNAs by choosing distinct combinations of splice sites within a messenger RNA precursor. This splicing enables mRNA from a single gene to synthesize different proteins, which have different cellular properties and functions and yet arise from the same single gene. A family of splicing factors, Serine-arginine rich proteins, are needed to initiate the assembly and activation of the spliceosome. Serine and arginine rich splicing factor 1, part of the arginine/serine-rich splicing factor protein family, can either activate or inhibit the splicing of mRNAs, depending on the phosphorylation status of the protein and its interaction partners. Considering that serine and arginine rich splicing factor 1 is either an activator or an inhibitor, this protein has been studied widely to identify its various roles in different diseases. Research has found that serine and arginine rich splicing factor 1 is a key target for neuroprotection, showing its promising potential use in therapeutics for neurodegenerative disorders. Furthermore, serine and arginine rich splicing factor 1 might be used to regulate cancer development and autoimmune diseases. In this review, we highlight how serine and arginine rich splicing factor 1 has been studied concerning neuroprotection. In addition, we draw attention to how serine and arginine rich splicing factor 1 is being studied in cancer and immunological disorders, as well as how serine and arginine rich splicing factor 1 acts outside the central or peripheral nervous system.
机标关键词：targetrichargininediseasesfactorneuroprotectionotherpotential
论文发表日期：2023-07-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 1411-1416 )
英文信息